Dyadic Secures Commercial Distribution Partnership with IBT Bioservices for Recombinant Proteins
DYAI sits 25% above its 52-week low of $0.711.
Summary
Dyadic Applied BioSolutions announced a commercial distribution partnership with IBT Bioservices, a life sciences reagent manufacturer and distributor. This agreement is a significant step for Dyadic, enabling the commercialization of its recombinant protein products, including DNase I and transferrin, through IBT's established global sales channels. The company views this as a crucial transition from R&D-driven revenue to product-based sales, aiming to expand market access and build durable revenue streams. This partnership follows a recent collaboration announcement with Inzymes ApS, indicating a strategic focus on commercializing its technology and expanding its product portfolio. For a company of Dyadic's market capitalization, securing a commercial distribution channel is a material development that could significantly impact future revenue potential. Investors will be watching for initial product sales and the financial impact of this new distribution channel.
At the time of this announcement, DYAI was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $0.71 to $1.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.